- PIs must submit an “Interim-RPPR” while their renewal application (Type 2) is under consideration. In the event that the Type 2 is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment. If the Type 2 is not funded, the Interim-RPPR will be treated by NIH staff as the institution’s Final-RPPR.
- PIs will be required to adhere to the new requirement to report on Project Outcomes. This section will be made publicly available, thus allowing recipients the opportunity to provide the general public with a concise summary of the cumulative outcome or findings of the project (analogous to the Project Summary/Abstract section of the competing application).
- NIH is aligning its reporting requirement with other federal research agencies and therefore will not be making any changes to the deadline for submitting the final report, i.e., the Final RPPR or Interim-RPPR must be submitted via eRA Commons no later than 120 calendar days from the period of performance end date.
- If a recipient fails to comply with this reporting requirement, NIH may take one or more enforcement actions, such as a decision not to make a non-competing continuation award.
- NIH will maintain the business rule in the RPPR module enabling institutional signing officials, at their discretion, to delegate submission of the Final RPPR or Interim-RPPR to the Program Director/Principal Investigator.
January 19, 2017 update: NIH Implementation of the Interim-RPPR while a Renewal Application is Under Consideration (NOT-OD-17-037).